Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Furthers Precision Cancer Ambitions With Foghorn Collaboration

Executive Summary

Building on its Loxo Oncology unit, Lilly teams with Foghorn to target cancers caused by BRG1 mutations, about 5% of all tumors, including 10% of NSCLC patients. Merck & Co. teamed up with Foghorn in 2020.

You may also be interested in...



Foghorn’s AML/MDS Trial Moved From Partial To Full Clinical Hold

A Phase I clinical trial of Foghorn’s FHD-286, which was placed on a partial hold in May after one death, is on a full hold now that multiple deaths may be attributed to differentiation syndrome.

Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold

The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.

Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020

Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel